ACAD
Price
$17.47
Change
+$0.54 (+3.19%)
Updated
May 9, 12:13 PM (EDT)
Capitalization
2.82B
82 days until earnings call
KOD
Price
$3.89
Change
-$0.11 (-2.75%)
Updated
May 9, 03:30 PM (EDT)
Capitalization
211.05M
10 days until earnings call
Ad is loading...

ACAD vs KOD

Header iconACAD vs KOD Comparison
Open Charts ACAD vs KODBanner chart's image
ACADIA Pharmaceuticals
Price$17.47
Change+$0.54 (+3.19%)
Volume$475
Capitalization2.82B
Kodiak Sciences
Price$3.89
Change-$0.11 (-2.75%)
Volume$2.49K
Capitalization211.05M
ACAD vs KOD Comparison Chart
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KOD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. KOD commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a StrongBuy and KOD is a Buy.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (ACAD: $16.93 vs. KOD: $4.00)
Brand notoriety: ACAD and KOD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 293% vs. KOD: 80%
Market capitalization -- ACAD: $2.82B vs. KOD: $211.05M
ACAD [@Biotechnology] is valued at $2.82B. KOD’s [@Biotechnology] market capitalization is $211.05M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileKOD’s FA Score has 1 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • KOD’s FA Score: 1 green, 4 red.
According to our system of comparison, KOD is a better buy in the long-term than ACAD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 4 TA indicator(s) are bullish while KOD’s TA Score has 6 bullish TA indicator(s).

  • ACAD’s TA Score: 4 bullish, 6 bearish.
  • KOD’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, KOD is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а +16.20% price change this week, while KOD (@Biotechnology) price change was -10.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.06%. For the same industry, the average monthly price growth was +11.12%, and the average quarterly price growth was -13.35%.

Reported Earning Dates

ACAD is expected to report earnings on Jul 30, 2025.

KOD is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (-5.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($2.82B) has a higher market cap than KOD($211M). ACAD YTD gains are higher at: -7.738 vs. KOD (-59.799). ACAD has higher annual earnings (EBITDA): 100M vs. KOD (-164.93M). ACAD has more cash in the bank: 756M vs. KOD (198M). ACAD has less debt than KOD: ACAD (52M) vs KOD (73.4M). ACAD has higher revenues than KOD: ACAD (958M) vs KOD (0).
ACADKODACAD / KOD
Capitalization2.82B211M1,338%
EBITDA100M-164.93M-61%
Gain YTD-7.738-59.79913%
P/E Ratio10.69N/A-
Revenue958M0-
Total Cash756M198M382%
Total Debt52M73.4M71%
FUNDAMENTALS RATINGS
ACAD vs KOD: Fundamental Ratings
ACAD
KOD
OUTLOOK RATING
1..100
1732
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
2594
PRICE GROWTH RATING
1..100
6239
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KOD's Valuation (26) in the Biotechnology industry is in the same range as ACAD (58). This means that KOD’s stock grew similarly to ACAD’s over the last 12 months.

KOD's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ACAD (100). This means that KOD’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's SMR Rating (25) in the Biotechnology industry is significantly better than the same rating for KOD (94). This means that ACAD’s stock grew significantly faster than KOD’s over the last 12 months.

KOD's Price Growth Rating (39) in the Biotechnology industry is in the same range as ACAD (62). This means that KOD’s stock grew similarly to ACAD’s over the last 12 months.

KOD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ACAD (100). This means that KOD’s stock grew similarly to ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADKOD
RSI
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 5 days ago
73%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 11 days ago
72%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
73%
Aroon
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KOD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RTXMX12.200.01
+0.08%
Russell Inv Tax-Managed Real Assets M
VEIEX29.25N/A
N/A
Vanguard Emerging Mkts Stock Idx Inv
LCILX24.95N/A
N/A
ClearBridge Sustainability Leaders IS
MIGOX27.56N/A
N/A
Marsico Global Institutional
FEGOX31.65-0.60
-1.86%
First Eagle Gold C

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with XNCR. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
+16.44%
XNCR - ACAD
45%
Loosely correlated
+10.08%
RGNX - ACAD
44%
Loosely correlated
-1.24%
CTMX - ACAD
43%
Loosely correlated
+13.48%
RCKT - ACAD
43%
Loosely correlated
+11.57%
RVMD - ACAD
42%
Loosely correlated
+11.29%
More

KOD and

Correlation & Price change

A.I.dvisor indicates that over the last year, KOD has been loosely correlated with RCKT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if KOD jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KOD
1D Price
Change %
KOD100%
+3.36%
RCKT - KOD
54%
Loosely correlated
+11.57%
XNCR - KOD
51%
Loosely correlated
+10.08%
RGNX - KOD
49%
Loosely correlated
-1.24%
KYMR - KOD
47%
Loosely correlated
+5.70%
BEAM - KOD
47%
Loosely correlated
+6.32%
More